However, Cramer notes that "these dividends now look less attractive versus bonds." Even the healthcare sector hasn't managed to make it out of May unscathed, falling by 7.05% year-to-date as of May 31. This sector's downfall, in particular, may shock many investors since it offers primarily dividend stocks. Over the same period, the utilities sector declined by 9.38%. Cramer stated that "oil and natural gas have been terrible investments this year." On the flip side, we have the losing sectors which Cramer uses as examples of "what happens if you do stray from tech." Losers in the S&P 500 include the energy sector, down 11.23% year-to-date as of May 31. While going through the winners of 2023 so far, Cramer noted that these sectors included companies that "are a who's who of artificial intelligence and friends," implying that those sectors that didn't stray from the "tech complex" managed to rise and continue rising all through May. The consumer discretionary sector was also a winner, rising by 19.25% year-to-date as of May 31. The communications services sector also managed to pull through, rising by 32.25% over the same period. He noted that the S&P 500 technology sector has been winning in May, rising by 34.81% year-to-date as of May 31. In another Mad Money episode that aired May 31, Cramer went through several S&P 500 sectors, sifting through the winners and the losers for his audience to be better prepared for this market. This preference for the company may very well stem from the fact that NVIDIA Corporation (NASDAQ:NVDA) seems to have "zero competition in the chip space," as Cramer himself noted.īut apart from NVIDIA Corporation (NASDAQ:NVDA), Cramer is also heavily bullish on many other companies, such as ON Semiconductor Corporation (NASDAQ: ON ) and Bristol-Myers Squibb Company (NYSE: BMY ). However, according to Cramer, NVIDIA Corporation's (NASDAQ:NVDA) Huang had told him years ago that "Moore's law was dead." He made this claim on the basis of the fact that "he came up with a way to make graphics cards that were more powerful and even more efficient, even if they were bigger because there was increasingly no benefit to shrinking semiconductors."īecause of NVIDIA Corporation's (NASDAQ:NVDA) undeniable success and its superior chips, major big tech companies have begun relying on it alone for their chips, especially if artificial intelligence is a space they wish to venture into. It received approval for two new drugs' Zepzelca & Rylaze'.While going over the potential NVIDIA Corporation (NASDAQ:NVDA) harnesses, Cramer mentioned Moore's law, a theory that implies that "chips will double in power every two years." This is a rule that has been governing the chip space for decades, placing limitations on what chip-makers can do. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. Jazz Pharmaceuticals Historical Annual Stock Price Data
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |